CD8A and neoplasm: Biomarkers of the treatment response, such as the determination of PD-L1 expression by immunohistochemistry, CD8+ T cell infiltration and distribution at tumor margins, and a high mutational load, which correlates with the clinical response to anti-PD-1/PD-L1 treatment, need to be standardized to improve their utility.